Showing 281 - 300 results of 17,441 for search '(( 5 ng decrease ) OR ( 50 ((((ng decrease) OR (we decrease))) OR (a decrease)) ))', query time: 0.44s Refine Results
  1. 281
  2. 282
  3. 283

    DataSheet1_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.ZIP by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  4. 284

    DataSheet2_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.xlsx by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  5. 285
  6. 286

    Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

    Published 2025
    “…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”
  7. 287
  8. 288
  9. 289
  10. 290
  11. 291

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  12. 292

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  13. 293
  14. 294
  15. 295
  16. 296
  17. 297
  18. 298
  19. 299

    Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

    Published 2021
    “…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”
  20. 300